肿瘤免疫治疗 z-bio 2025-03-05 425

　　Figure ICRAFT target discovery process, schematic diagram of targeting TNFAIP3 to promote tumor immunity in cancer cells and T cells

　　With the support of the National Natural Science Foundation of China's "Digital Decoding of Immunity" major research project (approval number: 92374116), researchers such as Zeng Zexian from Peking University's Frontier Interdisciplinary Research Institute, Pan Deng from Tsinghua University's School of Basic Medicine, and Gao Zhidong, chief physician at Peking University People's Hospital, have conducted collaborative research and made new progress in the discovery of tumor immunotherapy targets. The research findings, titled "Integrated Computational Analysis Identification of Therapeutic Targets with Dual Action in Cancer Cells and T Cells," were published on February 28, 2025 in the journal Immunity. The link to the paper is: https://doi.org/10.1016/j.immuni.2025.02.007 .

　　Tumor immunotherapy has made many breakthroughs in recent years, but there are still difficulties in screening therapeutic targets, killing cancer cells while damaging anti-cancer immune capabilities, and other issues. In response to the above challenges, researchers have developed an ICRAFT tumor immune target identification platform based on CRISPR genomics（ https://icraft.pku-genomics.org ）. As a fully open source online analysis platform, ICRAFT can provide interactive data analysis and high-quality, standardized data resources. The research team used the ICRAFT platform combined with cell and animal experiments to identify multiple key genes with dual regulatory abilities, such as TNFAIP3; Analyzed the mechanism of action of TNFAIP3 in the tumor microenvironment; Verified that targeting TNFAIP3 can both weaken the immune escape ability of tumor cells and enhance the anticancer efficacy of T cells; Provide important potential targets and theoretical basis for future development of combined immunotherapy strategies.